Trk Receptor

Receptor

Tropomyosin related kinase receptor

Trk Receptor

Trk Receptor Isoform Specific Products:

Trk Receptor Related Products (147)
Antibodies (9)
Trk Receptor Isoform Comparison

By Effects:	Control (1) Inhibitors (107) Agonists (11) Degrader (1) Antagonists (3) Activators (14) Modulators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-12678

Entrectinib	Inhibitor	99.79%
Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice.

HY-12866

Larotrectinib	Inhibitor	99.95%
Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-12497

ANA-12	Antagonist	99.90%
ANA-12 is a potent and selective TrkB antagonist with IC₅₀s of 45.6 nM and 41.1 μM for the high and low affinity sites, respectively.

HY-W013372

7,8-Dihydroxyflavone	Agonist	99.90%
7,8-Dihydroxyflavone is a potent and selective TrkB agonist that mimics the physiological actions of Brain-derived neurotrophic factor (BDNF). Displays therapeutic efficacy toward various neurological diseases.

HY-103022

Repotrectinib	Inhibitor	99.93%
Repotrectinib (TPX-0005) is a potent ROS1 (IC₅₀=0.07 nM) and TRK (IC₅₀=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC₅₀=1.01 nM). Repotrectinib has anti-cancer activity.

HY-168858

TRK-IN-30	Inhibitor
TRK-IN-30 (Compound C11) is the inhibitor for tropomyosin receptor kinase (TRK) that inhibits TRKA, TRKB and TRKC and drug resistant mutant TRKA^G595R with an IC₅₀ of 1.8, 0.98, 3.8, and 54 nM, respectively. TRK-IN-30 inhibits the activation of the downstream PI3K/AKT and MEK/ERK signaling pathways. TRK-IN-30 inhibits the colony formation and cell migration of Km-12, arrests the cell cycle at G0/G1 phase, and induces apoptosis in Km-12.

HY-169546

TrkA-IN-7	Inhibitor
TrkA-IN-7 (Compound 4) is an inhibitor of Tropomyosin Receptor Kinase A (TrkA) with a K_d value of 40 μM.

HY-170409

BNN27	Agonist
BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable.

HY-N6732

K-252a	Inhibitor	99.45%
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively. K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene.

HY-16961

Sitravatinib	Inhibitor	99.57%
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3/Flt-4, VEGFR2/KDR/Flk-1, VEGFR1/Flt-1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.

HY-107854

N-Acetyl-5-hydroxytryptamine	Activator	99.96%
N-Acetyl-5-hydroxytryptamine is a Melatonin precursor, and that it can potently activate TrkB receptor.

HY-B0527A

Amitriptyline hydrochloride	Agonist	99.94%
Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity.

HY-18314

GW 441756	Inhibitor	99.95%
GW 441756 is a potent and specific nerve growth factor (NGF) receptor tyrosine kinases A (TrkA) inhibitor (IC₅₀=2 nM), which eliminates the BmK NSPK-induced neurite outgrowth.

HY-104047

LM22B-10	Activator	99.92%
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.

HY-50867

Lestaurtinib	Inhibitor	99.17%
Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC₅₀s of 2, 25 and 0.9 nM for FLT3, TrkA and JAK2, respectively. Lestaurtinib induces apoptosis and cycle arrest, also can inhibit growth of tumor.

HY-P99221

Tanezumab	Antagonist	99.52%
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia.

HY-B0696A

Tiagabine hydrochloride	Modulator	99.44%
Tiagabine hydrochloride is an anticonvulsant agent and a selective inhibitor of the GAT-1 GABA transporter with a Ki of ～0.1 μM. Tiagabine hydrochloride potently and selectively inhibits GABA reuptake with IC₅₀s of 67, 446 and 182 nM for ^[3H]GABA uptake in synaptosomes, neurons and glia, respectively. Tiagabine hydrochloride has neuroprotective properties.

HY-B0527

Amitriptyline	Agonist	99.94%
Amitriptyline is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline has antidepressant activity.

HY-101977

Selitrectinib	Inhibitor	99.90%
Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor, with IC₅₀s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively.

HY-P1178

Cyclotraxin B	Inhibitor	98.11%
Cyclotraxin B is a BBB-penetrable and selective TrkB inhibitor. Cyclotraxin B inhibits BDNF-induced TrkB activity in a non-competitive manner, with an IC₅₀ of 0.30 nM. Cyclotraxin B has analgesic and anxiolytic effects.

Larotrectinib	TrkA	TrkB	TrkC		99.95%
ANA-12		TrkB			99.90%
7,8-Dihydroxyflavone		TrkB			99.90%
Repotrectinib	TrkA				99.93%
Sitravatinib	TrkA, IC₅₀: 5 nM	TrkB, IC₅₀: 9 nM			99.57%
N-Acetyl-5-hydroxytryptamine		TrkB			99.96%
Amitriptyline hydrochloride	TrkA	TrkB			99.94%
GW 441756	TrkA, IC₅₀: 2 nM				99.95%
LM22B-10		TrkB	TrkC		99.92%
Lestaurtinib	TrkA, IC₅₀: 25 nM				99.17%
Tiagabine hydrochloride		TrkB			99.44%
Selitrectinib	TrkA, IC₅₀: 0.6 nM		TrkC, IC₅₀: <2.5 nM		99.90%
Cyclotraxin B		TrkB			98.11%
GNF-5837	TrkA, IC₅₀: 11 nM	TrkB, IC₅₀: 9 nM	TrkC, IC₅₀: 7 nM		99.65%
Altiratinib	Trk1, IC₅₀: 0.85 nM	Trk2, IC₅₀: 4.6 nM	Trk3, IC₅₀: 0.93 nM		98.05%
Tamnorzatinib	TrkA				98.07%
Larotrectinib sulfate	TrkA	TrkB	TrkC		98.96%
AZ-23	TrkA, IC₅₀: 2 nM	TrkB, IC₅₀: 8 nM			98.92%
Tavilermide	TrkA				99.57%
HIOC		TrkB			99.94%
Tyrphostin AG 879	TrkA				99.85%
PF-06273340				TRK	98.8%
Belizatinib	TrkA	TrkB	TrkC		99.64%
Paltimatrectinib	TrkA				99.96%
CH7057288				TRK	99.73%
PF-6683324	TrkA, IC₅₀: 1.9 nM (in cell-based assays)	TrkB, IC₅₀: 2.6 nM (in cell-based assays)	TrkC, IC₅₀: 1.1 nM (in cell-based assays)		99.41%
Amitriptyline (hydrochloride) (Standard)	TrkA	TrkB			99.03%
DS-1205b free base	TrkA, IC₅₀: 407 nM				99.92%
CE-245677	TrkA				98.14%
TrkA-IN-3	TrkA, IC₅₀: 22.4 nM				98.46%
PF-06737007	TrkA, IC₅₀: 7.7 nM (in cell-based assays)	TrkB, IC₅₀: 15 nM (in cell-based assays)	TrkC, IC₅₀: 3.9 nM (in cell-based assays)		99.70%
TrkA-IN-4	TrkA				99.90%
TrkA-IN-1	TrkA, IC₅₀: 99 nM	TrkB, IC₅₀: 81 μM	TrkC, IC₅₀: 25 μM
Sitravatinib malate	TrkA, IC₅₀: 5 nM	TrkB, IC₅₀: 9 nM
LPM4870108	TrkA, IC₅₀: 2.4 nM		TrkC, IC₅₀: 0.2 nM
FLT3/TrKA-IN-1	TrkA, IC₅₀: 23.6 nM
PF-06733804	TrkA, IC₅₀: 8.4 nM (in cell-based assays)	TrkB, IC₅₀: 6.2 nM (in cell-based assays)	TrkC, IC₅₀: 2.2 nM (in cell-based assays)
KRC-108	TrkA, IC₅₀: 39 nM
Trk-IN-7	TrkA, IC₅₀: <25 nM	TrkB, IC₅₀: <5 nM	TrkC, IC₅₀: <25 nM
Trk-IN-8	TrkA		TrkC
Trk-IN-20	TrkA, IC₅₀: 1.6 nM	TrkB, IC₅₀: 2.9 nM	TrkC, IC₅₀: 2.0 nM
TRK-IN-23	TrkA, IC₅₀: 0.5 nM TRKA^G595R, IC₅₀: 14 nM TRKA^F589L, IC₅₀: 4.4 nM TRKA^G667C, IC₅₀: 4.8 nM		TrkC, IC₅₀: 9 nM
TIY-7	TrkA, IC₅₀: 2.9 nM
Cyclotraxin B TFA		TrkB
Protein kinase inhibitor 5 sulfate hydrate	TrkA, IC₅₀: 1.8 nM
Protein kinase inhibitor 5	TrkA, IC₅₀: 1.8 nM
Trk-IN-11	TrkA
(R)-Larotrectinib	TrkA, IC₅₀: 28.5 nM
TrkB-IN-1		TrkB
CZS-241	TrkA, IC₅₀: 2.74 μM
Trk-IN-10	TrkA
TRK II-IN-1	TrkA, IC₅₀: 3.3 nM	TrkB, IC₅₀: 6.4 nM	TrkC, IC₅₀: 4.3 nM
JND4135	TrkA	TrkB	TrkC
Multi-kinase-IN-6	TrkA, IC₅₀: 0.33 μM
Pan-Trk-IN-3	TrkA, IC₅₀: 2 nM	TrkB, IC₅₀: 3 nM	TrkC, IC₅₀: 2 nM
TrkC-IN-1			TrkC
Type II TRK inhibitor 1	TrkA		TrkC
D5261	TrkA
IHMT-TRK-284	TrkA, IC₅₀: 10.5 nM	TrkB, IC₅₀: 0.7 nM	TrkC, IC₅₀: 2.6 nM
Anizatrectinib	TrkA
NMS-P626	TrkA, IC₅₀: 8 nM	TrkB, IC₅₀: 3 nM	TrkC, IC₅₀: 7 nM
ONO-7579	TrkA
HS-345	TrkA
BNN-20		TrkB

Name
Email *

	Sorry, but the email address you supplied was invalid.

Trk Receptor

Trk Receptor

Trk Receptor Isoform Specific Products:

Trk Receptor Isoform Specific Products:

Trk Receptor Related Products (147)

Antibodies (9)

Trk Receptor Isoform Comparison

Trk Receptor Related Products (147):